H.C. Wainwright Reiterates Buy Rating on Genmab A/S (GMAB)

July 19, 2024 9:58 AM UTC Send to a Friend
H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $50.00 price target on Genmab A/S (NASDAQ: GMAB).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login